{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T10:45:16Z","timestamp":1742381116335,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Neyefonden"},{"name":"Rigshospitalets forskningsfond"},{"name":"John og Birthe Meyer Fonden"},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["670261","668532"],"award-info":[{"award-number":["670261","668532"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007460","name":"Arvid Nilssons Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001732","name":"Danmarks Grundforskningsfond","doi-asserted-by":"publisher","award":["126"],"award-info":[{"award-number":["126"]}],"id":[{"id":"10.13039\/501100001732","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Region Hovedstadens Forskningsfond"},{"DOI":"10.13039\/501100007324","name":"Sundhedsstyrelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s11307-022-01706-4","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T17:03:16Z","timestamp":1644944596000},"page":"600-611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Activity Dose Reduction in 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Impact on Image Quality and Lesion Detection Ability"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3024-5706","authenticated-orcid":false,"given":"Mathias","family":"Loft","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esben A.","family":"Carlsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla B.","family":"Johnbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoffer V.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flemming L.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seppo W.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Oturai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Knigge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-5547","authenticated-orcid":false,"given":"Andreas","family":"Kjaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"1706_CR1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A et al (2008) One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in The United States. J Clin Oncol 26:3063\u20133072","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1706_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000080742","volume":"80","author":"JC Reubi","year":"2004","unstructured":"Reubi JC (2004) Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80(Suppl 1):51\u201356","journal-title":"Neuroendocrinology"},{"key":"1706_CR3","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"MF Bozkurt","year":"2017","unstructured":"Bozkurt MF, Virgolini I, Balogova S et al (2017) Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging 44:1588\u20131601","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1706_CR4","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/0284186X.2021.1921262","volume":"60","author":"ET Janson","year":"2021","unstructured":"Janson ET, Knigge U, Dam G et al (2021) Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol 60:931\u2013941","journal-title":"Acta Oncol"},{"key":"1706_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000458155","volume":"105","author":"U Knigge","year":"2017","unstructured":"Knigge U, Capdevila J, Bartsch DK et al (2017) ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms: follow-up and documentation. Neuroendocrinology 105:310\u2013319","journal-title":"Neuroendocrinology"},{"key":"1706_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","volume":"46","author":"JR Strosberg","year":"2017","unstructured":"Strosberg JR, Halfdanarson TR, Bellizzi AM et al (2017) The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas 46:707\u2013714","journal-title":"Pancreas"},{"key":"1706_CR7","first-page":"1","volume":"37","author":"ICRP","year":"2007","unstructured":"ICRP (2007) Radiological protection in medicine. Ann ICRP 37:1\u201363","journal-title":"Ann ICRP"},{"key":"1706_CR8","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335\u20131342","journal-title":"JAMA Oncol"},{"key":"1706_CR9","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.ejso.2018.01.082","volume":"44","author":"LL Cao","year":"2018","unstructured":"Cao LL, Lu J, Lin JX et al (2018) Incidence and survival trends for gastric neuroendocrine neoplasms: an analysis of 3523 patients in the SEER database. Eur J Surg Oncol 44:1628\u20131633","journal-title":"Eur J Surg Oncol"},{"key":"1706_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2967\/jnumed.116.180430","volume":"58","author":"CB Johnbeck","year":"2017","unstructured":"Johnbeck CB, Knigge U, Loft A et al (2017) Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET\/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med 58:451\u2013457","journal-title":"J Nucl Med"},{"key":"1706_CR11","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2967\/jnumed.115.156539","volume":"56","author":"A Pfeifer","year":"2015","unstructured":"Pfeifer A, Knigge U, Binderup T et al (2015) 64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients. J Nucl Med 56:847\u2013854","journal-title":"J Nucl Med"},{"key":"1706_CR12","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2967\/jnumed.111.101469","volume":"53","author":"A Pfeifer","year":"2012","unstructured":"Pfeifer A, Knigge U, Mortensen J et al (2012) Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med 53:1207\u20131215","journal-title":"J Nucl Med"},{"key":"1706_CR13","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.2217\/fon.14.139","volume":"10","author":"CB Johnbeck","year":"2014","unstructured":"Johnbeck CB, Knigge U, Kjaer A (2014) PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol 10:2259\u20132277","journal-title":"Future Oncol"},{"key":"1706_CR14","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2967\/jnumed.119.236091","volume":"61","author":"ES Delpassand","year":"2020","unstructured":"Delpassand ES, Ranganathan D, Wagh N et al (2020) 64Cu-DOTATATE PET\/CT for imaging patients with known or suspected somatostatin receptor-positive neuroendocrine tumors: results of the first U.S. prospective, reader-masked clinical trial. J Nucl Med 61:890\u2013896","journal-title":"J Nucl Med"},{"key":"1706_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40658-016-0144-5","volume":"3","author":"M Conti","year":"2016","unstructured":"Conti M, Eriksson L (2016) Physics of pure and non-pure positron emitters for PET: a review and a discussion. Ejnmmi Phys 3:8","journal-title":"Ejnmmi Phys"},{"key":"1706_CR16","unstructured":"Orange Book: approved drug products with therapeutic equivalence evaluations. U.S. Food and Drug Administration website. Detectnet Label.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213227s000lbl.pdf. Accessed 7 Jan\u00a02022"},{"key":"1706_CR17","unstructured":"Orange Book: approved drug products with therapeutic equivalence evaluations. U.S. Food and Drug Administration website. Netspot Label.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208547s000lbl.pdf. Accessed 7 Jan\u00a02022"},{"key":"1706_CR18","unstructured":"Orange Book: approved drug products with therapeutic equivalence evaluations. U.S. Food and Drug Administration website. Ga 68 Dotatoc Label.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/210828s002lbl.pdf. Accessed 7 Jan\u00a02022"},{"key":"1706_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2967\/jnumed.120.244509","volume":"62","author":"M Loft","year":"2021","unstructured":"Loft M, Carlsen EA, Johnbeck CB et al (2021) 64Cu-DOTATATE PET in patients with neuroendocrine neoplasms: prospective, head-to-head comparison of imaging at 1 hour and 3 hours after injection. J Nucl Med 62:73\u201380","journal-title":"J Nucl Med"},{"key":"1706_CR20","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.2967\/jnumed.119.240143","volume":"61","author":"EA Carlsen","year":"2020","unstructured":"Carlsen EA, Johnbeck CB, Binderup T et al (2020) 64Cu-DOTATATE PET\/CT and prediction of overall and progression-free survival in patients with neuroendocrine neoplasms. J Nucl Med 61:1491\u20131497","journal-title":"J Nucl Med"},{"key":"1706_CR21","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.2967\/jnumed.120.258392","volume":"62","author":"EA Carlsen","year":"2021","unstructured":"Carlsen EA, Johnbeck CB, Loft M et al (2021) Semi-automatic tumor delineation for evaluation of 64Cu-DOTATATE PET\/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume. J Nucl Med 62:1564\u20131570","journal-title":"J Nucl Med"},{"key":"1706_CR22","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.2967\/jnumed.120.257808","volume":"61","author":"TA Hope","year":"2020","unstructured":"Hope TA (2020) Updates to the appropriate-use criteria for somatostatin receptor PET. J Nucl Med 61:1764","journal-title":"J Nucl Med"},{"key":"1706_CR23","unstructured":"National Comprehensive Cancer Network (2021) Neuroendocrine and adrenal tumors (Version 4.2021).\u00a0https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf. Accessed 7 Jan\u00a02022"},{"key":"1706_CR24","first-page":"15","volume":"19","author":"S Gatidis","year":"2016","unstructured":"Gatidis S, Wurslin C, Seith F et al (2016) Towards tracer dose reduction in PET studies: Simulation of dose reduction by retrospective randomized undersampling of list-mode data. Hell J Nucl Med 19:15\u201318","journal-title":"Hell J Nucl Med"},{"key":"1706_CR25","doi-asserted-by":"publisher","first-page":"764","DOI":"10.2967\/jnumed.119.234351","volume":"61","author":"J van Sluis","year":"2020","unstructured":"van Sluis J, Boellaard R, Dierckx R et al (2020) Image quality and activity optimization in oncologic 18F-FDG PET using the digital biograph vision PET\/CT system. J Nucl Med 61:764\u2013771","journal-title":"J Nucl Med"},{"key":"1706_CR26","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/diagnostics11020350","volume":"11","author":"M Loft","year":"2021","unstructured":"Loft M, Johnbeck CB, Carlsen EA et al (2021) Initial experience with 64Cu-DOTATATE digital PET of patients with neuroendocrine neoplasms: comparison with analog PET. Diagnostics 11:350","journal-title":"Diagnostics"},{"key":"1706_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2967\/jnumed.119.231845","volume":"61","author":"AR Pantel","year":"2020","unstructured":"Pantel AR, Viswanath V, Daube-Witherspoon ME et al (2020) PennPET Explorer: Human imaging on a whole-body imager. J Nucl Med 61:144\u2013151","journal-title":"J Nucl Med"},{"key":"1706_CR28","doi-asserted-by":"publisher","unstructured":"Virgolini I, Bahri S, Kjaer A et al (2021) A randomised, factorial phase II study to determine the optimal dosing regimen for 68Ga-satoreotide trizoxetan as an imaging agent in patients with gastroenteropancreatic neuroendocrine tumours. J Nucl Med. https:\/\/doi.org\/10.2967\/Jnumed.121.261936","DOI":"10.2967\/Jnumed.121.261936"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01706-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-022-01706-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01706-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T13:18:29Z","timestamp":1658236709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-022-01706-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1706"],"URL":"https:\/\/doi.org\/10.1007\/s11307-022-01706-4","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"type":"print","value":"1536-1632"},{"type":"electronic","value":"1860-2002"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"assertion":[{"value":"6 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research study was conducted retrospectively in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards following approval by the Danish Patient Safety Authority (Ref 31\u20131521-453) according to Danish regulations. For this type of study, formal consent is not required. All the procedures being performed were part of the patient\u2019s routine care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"U.K. and A.K. are inventors\/holds intellectual property rights on a patent covering [<sup>64<\/sup>Cu]Cu-DOTATATE. All other authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}